Mirati

Mirati Therapeutics, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of targeted therapies for cancer. The company is headquartered in San Diego, California, and operates primarily in the United States with additional activities internationally. Mirati's portfolio centers on small-molecule agents designed to inhibit oncogenic proteins implicated in tumor growth, with a current emphasis on KRAS-driven cancers.

A flagship program is adagrasib (MRTX849), a KRAS G12C inhibitor developed to treat multiple KRAS G12C-mutant cancers. In addition to adagrasib, Mirati maintains a broader oncology pipeline aimed at other genetic alterations and tumor dependencies, including early- and mid-stage programs across solid tumors and hematologic malignancies. The company pursues both internally derived candidates and external collaborations to advance its portfolio through preclinical and clinical development.

Corporate and financial aspects: Mirati Therapeutics is a publicly traded company listed on the NASDAQ stock market under the ticker MRTX. It funds its activities through a combination of research and development investment, collaboration agreements, and product potential revenue if approved. As with many clinical-stage biotechnology firms, Mirati reports periods of operating losses or net income fluctuations tied to the progress of clinical trials and regulatory milestones.

See also: adagrasib, KRAS, oncology drug development.